Gut Microbiota Market Share

North American Market Forecast

The market share of gut microbiota in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 35% by the end of 2036. The growth of the market can be attributed majorly to the rising concern about digestive illnesses such as gastroesophageal reflux disease (GERD) as well as other lifestyle disorders owing to the growing sedentary lifestyle, remote jobs, junk foods, and others. For instance, as per a study in 2022, nearly 20% of the U.S. population was affected by GERD or chronic acid reflux. Moreover, the rising spending on health care in the region is further expected to enhance the gut microbiota market in the region.

Europe Market Forecast

The European gut microbiota market is estimated to be the second largest, registering a share of about 25% by the end of 2036. The growth of the market can be attributed majorly to the rapidly rising geriatric population as well as the growing ubiquity of heart diseases and other chronic diseases coupled with the increasing research & development and clinical trials in the field of microbiome therapy in the region. It was found that over one-fifth or over 21% of the European Union population was aged 65 and over in 2022. Moreover, the increasing awareness of preventive healthcare in the region is further anticipated to propel regional market growth.

APAC Market Statistics

Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The presence of a vast pool population as well as the growing prevalence of autoimmune diseases such as celiac diseases, diabetes, asthma, cancer, and others in the region coupled with the increasing prevalence of obesity and other lifestyle-related diseases. For instance, a study conducted in 2019, recruiting nearly 19,778 Chinese adolescents and young adults, showed that the prevalence of celiac disease autoimmunity reached nearly 2.19% in the country. Moreover, diabetes prevalence in Chinese adults is estimated to rise from 8% to around 9.5% among the age group of 20–79 years between 2020-2030.